Racial and Socioeconomic Disparities in Presentation and Outcomes of Well-Differentiated Thyroid Cancer

被引:119
|
作者
Harari, Avital [1 ]
Li, Ning [2 ]
Yeh, Michael W. [1 ]
机构
[1] Univ Calif Los Angeles, Sect Endocrine Surg, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90095 USA
来源
关键词
UNITED-STATES; HEALTH DISPARITIES; AFRICAN-AMERICANS; BREAST-CANCER; INCREASING INCIDENCE; ETHNIC-GROUPS; SURVIVAL; WOMEN; RISK; CARE;
D O I
10.1210/jc.2013-2781
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Racial/ethnic minorities suffer disproportionate morbidity and mortality from chronic diseases. Objective: Our objective was to assess racial and socioeconomic status (SES) disparities in well-differentiated thyroid cancer (WDTC) patients. Design and Participants: We conducted a retrospective cohort study on 25 945 patients with WDTC (1999-2008) from the California Cancer Registry (57% white, 4% black, 24% Hispanic, and 15% Asian-Pacific Islander [API]). Main Outcomes: We evaluated effect of race and SES variables on stage of cancer presentation and overall/disease-specific survival. Results: Significant differences in stage of presentation between all racial groups were found (P < .001), with minority groups presenting with a higher percentage of metastatic disease as compared with white patients (black, odds ratio [OR] = 1.36 with confidence interval [CI] 1.01-1.84; Hispanic, OR = 1.89 [CI, 1.62-2.21], API, OR = 1.82 [CI, 1.54-2.15]). Hispanic (OR = 1.59, [CI, 1.48-1.72]) and API (OR = 1.32 [1.22-1.44]) patients also presented with higher odds of regional disease. Patients with the lowest SES presented with metastatic disease more often than those with the highest SES (OR = 1.45 [CI, 1.16-1.82]). Those that were poor/uninsured and/or with Medicaid insurance had higher odds of presenting with metastatic disease as compared with those with private insurance (OR = 2.41, [CI, 2.10-2.77]). Unadjusted overall survival rates were higher among API and Hispanic patients and lower among black patients (P < .001 vs white patients). Adjusted overall survival also showed a survival disadvantage for black patients (hazard ratio = 1.4, [CI, 1.10-1.73]) and survival advantage for API patients (hazard ratio = 0.83, [CI, 0.71-0.97]). In disease-specific survival analyses, when only those patients with metastatic disease were analyzed separately, black patients again had the lowest survival rates, and Hispanic/API patients had the highest survival rates (P < .04). Conclusion: Black patients and those with low SES have worse outcomes for thyroid cancer. API and Hispanic patients may have a protective effect on survival despite presenting with more advanced disease.
引用
收藏
页码:133 / 141
页数:9
相关论文
共 50 条
  • [21] Conservative management of well-differentiated thyroid cancer
    Hassanain, Mazen
    Wexler, Marvin
    CANADIAN JOURNAL OF SURGERY, 2010, 53 (02) : 109 - 118
  • [22] Management of the Neck in Well-Differentiated Thyroid Cancer
    Panagiotis Asimakopoulos
    Ashok R. Shaha
    Iain J. Nixon
    Jatin P. Shah
    Gregory W. Randolph
    Peter Angelos
    Mark E. Zafereo
    Luiz P. Kowalski
    Dana M. Hartl
    Kerry D. Olsen
    Juan P. Rodrigo
    Vincent Vander Poorten
    Antti A. Mäkitie
    Alvaro Sanabria
    Carlos Suárez
    Miquel Quer
    Francisco J. Civantos
    K. Thomas Robbins
    Orlando Guntinas-Lichius
    Marc Hamoir
    Alessandra Rinaldo
    Alfio Ferlito
    Current Oncology Reports, 2021, 23
  • [23] Therapeutic Outcomes of Recurrent Well-Differentiated Thyroid Carcinomas
    Tsai, Chih-Yiu
    Lin, Shu-Fu
    Chen, Szu-Tah
    Hsueh, Chuen
    Lin, Yann Sheng
    Lin, Jen-Der
    INTERNATIONAL SURGERY, 2019, 104 (7-8) : 304 - 313
  • [24] A Clinical Nomogram to Predict Survival Outcomes in Patients with Well-Differentiated Thyroid Cancer
    Valero, Cristina
    Eagan, Alana
    Adilbay, Dauren
    Matsuura, Danielli
    Harries, Victoria
    Shaha, Ashok R.
    Shah, Jatin P.
    Tuttle, R. Michael
    Akhmedin, Darkhan
    Pinheiro, Renan Aguera
    Matos, Leandro Luongo
    Kowalski, Luiz P.
    Adilbayev, Galym
    Kadyrbayeva, Rabiga
    Patel, Snehal G.
    Ganly, Ian
    THYROID, 2025,
  • [25] Well-differentiated carcinoma of the thyroid
    Boone, RT
    Fan, CY
    Hanna, EY
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2003, 36 (01) : 73 - +
  • [26] Well-differentiated thyroid carcinoma
    Segal, K
    Raveh, E
    Lubin, E
    Abraham, A
    Shvero, J
    Feinmesser, R
    AMERICAN JOURNAL OF OTOLARYNGOLOGY, 1996, 17 (06) : 401 - 406
  • [27] Reoperation for Recurrent/Persistent Well-Differentiated Thyroid Cancer
    Pai, Sara I.
    Tufano, Ralph P.
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2010, 43 (02) : 353 - +
  • [28] Prognosis and Management of Invasive Well-differentiated Thyroid Cancer
    Urken, Mark L.
    OTOLARYNGOLOGIC CLINICS OF NORTH AMERICA, 2010, 43 (02) : 301 - +
  • [29] Selective Surgical Management of Well-Differentiated Thyroid Cancer
    Shaha, Ashok
    RECENT ADVANCES IN CLINICAL ONCOLOGY, 2008, 1138 : 58 - 64
  • [30] Mutation Profile of Well-Differentiated Thyroid Cancer in Asians
    Song, Young Shin
    Lim, Jung Ah
    Park, Young Joo
    ENDOCRINOLOGY AND METABOLISM, 2015, 30 (03) : 252 - 262